Table 1.

Itch secondary to chronic kidney disease (CKD)

Study	Country	Design	N of subjects	Drugs	Via	Duration	Instrument	Type of itch	Results
Solak Y et al., 2012	England	Prospective, randomized, crossover, comparative	50	Gabapentin 300 mg 3x/ week Pregabalin 75mg/day	Oral	14 weeks (6 weeks for each drug; 2 weeks WO)	VAS	Peripheral neuropathy in patients in dialysis	Significantly decrease in symptoms, with no difference between the two drugs
Marquez D et al., 2012	Argentina	prospective, nonrandomized,	22	Gabapentin 300 mg 3x/ week of desloratadine 5mg 3x/week	Oral	7 weeks (3 weeks each drug; 1 week WO)	VAS	dialysis	Only desloratadine had statistical significance
Gunal AI et al., 2004	Turkey	Prospective, randomized, placebo-controlled, double-blind	25	Gabapentin 300mg or placebo	Oral	9 weeks (4 weeks each drug; 1 week WO)	VAS	dialysis	Decreased score showed highly significance (0.0001) after gabapentin
Razeghi E et al., 2009	Iran	Prospective, placebo-controlled, double-blind	34	Gabapentin 100mg or placebo 3x/weeks	Oral	9 weeks	VAS	dialysis	Effectiveness of gabapentin in low doses
Naini AE et al., 2007	Iran	Longitudinal, randomized placebo-controlled	34	Gabapentin 400mg Placebo	Oral	4 weeks	VAS	dialysis	Gabapentin was effective
Pour- Reza- GholiF. et al., 2007	Iran	Prospective, randomized, placebo-controlled, double-blind, crossover	24	Doxepin 10mg 2x/day Placebo	Oral	3 weeks (1 week each group; 1 week WO)	Clinical improvement	dialysis	Doxepin with significant improvement

Legend: WO- washout; VAS: Visual Analogue Scale